TEMBEXA

PeakSM

brincidofovir

NDAORALSUSPENSIONPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10

Clinical Trials (5)

NCT05935917Phase 1Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

Started May 2023
44 enrolled
Smallpox
NCT03532035Phase 2Withdrawn

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

Started Dec 2018
0
Adenovirus
NCT02439970Phase 3Terminated

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

Started Sep 2015
5 enrolled
Cytomegalovirus Disease
NCT02439957Phase 3Terminated

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

Started Sep 2015
6 enrolled
Cytomegalovirus DiseaseKidney Transplant Infection
NCT04268966Phase 2Withdrawn

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Started Oct 2014
0
Ebola Virus Disease

Loss of Exclusivity

LOE Date
Aug 31, 2031
66 months away
Patent Expiry
Aug 31, 2031
Exclusivity Expiry
Jun 4, 2028

Patent Records (1)

Patent #ExpiryTypeUse Code
9303051
Aug 31, 2031
SubstanceProduct
U-3165